Role of hydrogen sulphide in airways

Table 1 Hydrogen sulfide concentration in healthy subjects and patients with asthma, chronic obstructive pulmonary disease or pneumonia

Subjects	Age(yr)	H2S concentration in serum/plasma (μmol/L)	Ref.
Healthy
	71-80	35.7 ± 1.2	[16]
	61-70	34.0 ± 0.9	[16]
	50-60	36.4 ± 1.1	[16]
	64.1 ± 8.7	35.4 ± 5.3	[43]
	9.22 ± 1.80	52.60 ± 5.56	[17]
Patients with bronchial asthma
Bronchial asthma	6-12	44.17 ± 10.95	[17]
Neutrophilic group	53.0 ± 13.9	8.8 ± 4.7	[46]
Paucigranulocytic group	45.5 ± 15.7	6.9 ± 2.0	[46]
	9.03 ± 1.84	44.17 ± 10.95	[17]
Patients with stable COPD
Patients with acute exacerbations of COPD
	73.9 ± 8.3	33.8 ± 18.6	[43]
Patients in stage I to II	65.6 ± 1.6	40.5 ± 6.3	[16]
Patients in stage III		33.4 ± 2.9	[16]
Patients in stage IV		27.6 ± 1.6	[16]
Patients with pneumonia	57.6 ± 20.4	22.7 ± 14.6	[43]
		H2S concentration in exhaled air (ppb)
Healthy	52.86 ± 19.81	8.0-16.0	[18]
Patients with bronchial asthma
Eosinophilic group	46.0 ± 15.2	7.7 ± 4.2	[46]
Paucigranulocytic group	45.5 ± 15.7	11.1 ± 4.6	[46]
Patients with COPD
Acute exacerbations	67.5 ± 11.47	8.0-13.0	[18]
Stable COPD	64.11 ± 8.79	9.0-12.0	[18]

H₂S: Hydrogen sulfide; COPD: Chronic Obstructive Pulmonary Disease.